Find and Pitch Jounalists, Get Your Story Covered

Tags: Algae Biotechnology Sustainability Microalgae Acino M8 Pharmaceuticals

	Profile	Recent Articles on Subject
1	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 4 days ago STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - about 2 months ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - 12 months ago
2	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study - 6 days ago STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 7 days ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 3 months ago STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells - 5 months ago STAT+: Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines - 6 months ago STAT+: Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies - 6 months ago STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit - 12 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 days ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 days ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 15 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 2 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 5 months ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago Virtual Event: March of the Biosimilars - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago
4	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 8 days ago
5	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire - 8 days ago STAT+: Tome Biosciences files notice to lay off virtually entire staff - 27 days ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 28 days ago STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain - about 2 months ago STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field - 3 months ago STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy - 3 months ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 14 days ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 14 days ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: The inside story of Enhertu’s pan-tumor approval - 5 months ago STAT+: Weed for weight loss, and more from Biotech Land - 6 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 6 months ago Listen: Live! From the STAT Breakthrough Summit East - 6 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - 9 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 9 months ago STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead - 10 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 15 days ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 28 days ago STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - about 2 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 4 months ago STAT+: Biotech startups post strongest financing numbers in two years - 5 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 6 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 6 months ago Listen: Live! From the STAT Breakthrough Summit East - 6 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - 11 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - about 1 month ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 2 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 4 months ago
9	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback - about 1 month ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 3 months ago STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 4 months ago STAT+: Nvidia says a biological revolution is happening now. But is it? - 8 months ago
10	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: Why clinical trials for digital therapeutics are getting more rigorous - 2 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 6 months ago

Journalists covering biotechnology | Pharmaceuticals | STAT+